THE Sisters of the Valley, a group of self-ordained "marijuana nuns," are putting their religion on the powers of cannabis to help heal the world. The non-religious sect, made up of a brotherhood of radical feminists, was founded by Sister Kate, 62, a self-proclaimed "activist anarchist nun," in 2015 in Northern California's Merced County. Women grow and harvest their own cannabis plants to create holistic medicinal products, reminiscent of the cannabidiol (CBD) ointments, tinctures, balms and soaps sold online. They use a variety of marijuana that eliminates the psychoactive compound THC, but still contains CBD, which has been touted to help treat everything from epilepsy to most cancers and addiction. Sister Kate, whose real name is Christine Meeusen, started the business with just 12 plants, yet since then the organization has grown into a global team that, until the pandemic, generated profits of more than $ 1.1 million. Despite the group's nickname, Sister Kate told The Solar that the Valley Sisters are under no circumstances affiliated with the Catholic Church.
The company's premier brand focuses on creating created experiences. The Cronos brands are aimed at a wide range of consumers who are looking for leisure and fun ways to boost their actions. Cronos also has upbeat and fun brands that may be focused on offering merchandise that delivers friends and makes experiences more enjoyable. The company develops a preeminent CBD brand in the US In the US Cronos focuses on premium US 900 stores of high quality. Retail channels. Cronos recently launched an American CBD brand in the United States. The product arises from the assumption that being pleasant can result in a better world full of positivity and risk. It is a belief that extends beyond merchandise and encompasses everything the brand seeks to do and defend. The brand intends to distribute merchandise through the mass market focused retail channel within the U.S. Cronos has developed a diversified international network of gross sales and distribution by leveraging established companions for company scale, the sales force and market experience. The company has also created a distribution footprint in Canada through the direct-to-buyer medical market and adult use market, in addition to a distribution footprint for customer products derived from hemp in the US market demand and to create and scale even more America. Cronos intends to enter the US The company is currently selling dry cannabis. Cannabis is extracted directly to buyers through the Cronos wellness platform. Sometimes clients are obtained through a doctor. Clinical references or word of mouth recommendations from current buyers.
Cronos Group (TSX: CRON) (NASDAQ: CRON) is a modern international cannabinoid (CBD) company with international manufacturing and distribution on five continents. Cronos Group builds disruptive intellectual property by promoting cannabis research, expertise and product development. The company is within the art of building a portfolio of iconic models that responsibly elevates the consumer experience. In the United States, Cronos markets and distributes exclusively in the United States. In Canada, the company sells a variety of cannabis and cannabis products, along with dry cannabis, pre-rolls and cannabis extracts through wholesale and direct-to-customer channels under the company's wellness platform. Additionally, dried cannabis and cannabis oils are currently exported on the market to Australia, Germany and Israel. The company currently distributes products to Canada and outside of the US Through the company's global wellness platform, Cronos produces high-quality cannabis and cannabis products and is focused on building and shaping the global cannabis wellness market and promote a holistic approach to wellness. The goal of the brand is to improve the lives of other consumers, consumer to consumer.
In general, analysts are not impressed with OGI's inventory. For example, TipRanks reports that the average target value of eight analysts who have written to OGI inventory so far three months is just $ 2.34. That represents a potential drop of 47% from the current value. Looking for Alpha finds that sixteen analysts have an average target value of $ 2.76. However, Marketbeat indicates that its survey of 12 analysts has a consensus goal of $ 2.93. The fundamental problem is that the company needs to demonstrate to the market that it has a sustainable and worthwhile business model. For example, this past quarter its median sale value was CAD 3.31 per gram, based on its most recent SEC quarterly financial filing (website 8). This, frankly, is a hindrance to your pursuit of profit. However, the company hopes to promote extra edibles and cannabis drinks. It's because more people are "not interested in smoking or vaping" cannabis. The problem is your "other" and international revenue represents only about 1% of total gross gross sales.
The sad truth is that he makes most of his money selling cannabis products. I believe that until the company can enter the sales of cannabinoids (CBD) or related devices to diversify solely from cannabis, its margins will be negligible. There is some light at the end of the tunnel. In its earnings statement, Organigram stated that it is cutting guide labor costs through automation tools. However, there are no earnings forecasts, margin target numbers, or forecasts to stick with CFFO earnings. Until Organigram can produce these forecasts or test them against real numbers, OGI's inventory will be stagnant. Most investors will need to stay away from him until he has a real prospect of becoming profitable, in any form of that phrase. At the time of publication, Mark R. Hake did not have an extended position orshort on none of the values in this text. It doesn't matter if you have $ 500 in savings or $ 5 million.